HUDSON, N.H., Sept. 08, 2016 -- S-BIO1 has launched today EZGlycoTM mAb-N Kit with 2-AB, a breakthrough new product that enables scientists to analyze N-glycans in IgG and Fc-fusion proteins from culture supernatant samples in a rapid, simplified and streamlined single tube operation. The kit is a valuable tool supporting customers in glycoprotein characterization for biotherapeutic development.
Therapeutic monoclonal antibodies (IgG, mAb) are routinely expressed in recombinant expression systems. N-glycosylation is one of the most important post-translational modifications. Monitoring of glycosylation in antibody development and production directly from cell culture media will shorten the time needed to obtain the N-glycan profiling. HPLC-ready glycan preparation can be performed in less than 2 hours, allowing scientists to purify IgG from cell culture supernatant, release and label N-glycans in one complete kit. “The EZGlyco mAb-N Kit with 2-AB streamlined and rapid N-glycan preparation from IgG cell culture supernatant circumvents use of other kits for IgG purification and provides unmatched speed, ease of use, and compatibility with HPLC,” states Dr. Anju M. Dang, Director, S-BIO.
The new EZGlycoTM mAb-N Kit with 2-AB is currently available in the U.S. through S-BIO, Vaupell Holdings Inc. (http://s-bio.com/products/ezglyco-mab-n/), a Sumitomo Bakelite Co., Ltd. group company.
About S-BIO
S-BIO is a division of Sumitomo Bakelite Co., Ltd. (a pioneer in plastics with products used for wide-ranging applications such as IT components and material, high performance plastics and quality-of-life product). S-BIO’s main product and services fall into two categories: glycan analysis related services and products, and high performance labware for cell culture applications.
Glossary
1S-BIO, U.S.
S-BIO is a division of Sumitomo Bakelite that specializes in providing glycan analysis products and tools to advance glycomics research, and 3D cell culture plates for cancer and stem cell research.
S-BIO’s analytical services are based on a proprietary GlycanMap® platform, which provides rapid and efficient analysis of both N-linked and O-linked glycans in glycoproteins. GlycanMap® technology combines BlotGlyco® bead-based glycan purification in a fully automated sample processing system with high-throughput MALDI-TOF mass spectrometry to generate rapid, reproducible glycan profiles for bioprocess and biomarker discovery. With an established laboratory at Hudson, NH, S-BIO supports the advancement of customer needs in the fields of drug discovery, regenerative medicine, stem cell and cancer research, and glycobiology.
Registered trademarks are trademarks of their respective companies.
Anju M. Dang, Ph.D. S-BIO, Sumitomo Bakelite Co., Ltd. Tel: (603) 425-9697 E-mail: [email protected]


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Instagram Outage Disrupts Thousands of U.S. Users
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



